Key result
Recombinant human ANGPTL4 reduced brain edema and hematoma volume and improved neurological functional recovery over 4 weeks compared with vehicle in a mouse model of intracerebral hemorrhage.
Why the study?
Does rhANGPTL4 reduce brain edema and improve neurological function in a mouse model of intracerebral hemorrhage?
Does rhANGPTL4 reduce brain edema and improve neurological function in a mouse model of intracerebral hemorrhage?
Prophylactic administration of ANGPTL4 reduces brain edema and improves neurological recovery in a mouse model of intracerebral hemorrhage.
May attenuate edema and aid recovery after experimental ICH; leaves open translation to clinical use.
BACKGROUND Angiopoietin-like 4 (ANGPTL4) is neuroprotective when administered acutely for the treatment of cerebral ischemia. The aim of the present study was to evaluate the preventive effects of ANGPTL4 on the formation of brain edema and to determine whether it promotes the recovery of neurological function following intracerebral hemorrhage (ICH). MATERIAL AND METHODS Recombinant human ANGPTL4 (rhANGPTL4; 40 µg/kg) or a vehicle was administered intraperitoneally 5 min prior to bacterial collagenase-induced ICH in male C57/B6J mice. Behavioral tests were performed prior to ICH and at days 1, 3, 7, 14, 21, and 28 after ICH. Brain edema and hematoma volume were examined separately using the wet weight/dry weight method and hematoxylin-eosin staining. The integrity of the tight and adherens junctions was quantified via immunofluorescence. The ultrastructure of the blood-brain barrier (BBB) was examined using transmission electron microscopy. Vascular endothelial (VE)-cadherin, claudin-5, Src, and phospho-Src in the ipsilateral and contralateral striatum were detected by Western blot analysis. RESULTS RhANGPTL4 reduced brain edema and hematoma volume and improved neurological functional recovery over the subsequent 4 weeks when compared with the control group. rhANGPTL4 significantly increased VE-cadherin and claudin-5-positive areas and relative amounts in the peri‑hematoma region compared with the control group. In addition, ANGPTL4 significantly reduced the ratio of phospho-Src to Src. The significant reduction of Src kinase activity in the peri‑hematoma region of ANGPTL-treated mice was paralleled by a decrease in vascular permeability and edema formation. CONCLUSIONS These results suggest that ANGPTL4 is a relevant target for vasculoprotection and cerebral protection during stroke.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2018) studied Intracerebral hemorrhage. Recombinant human ANGPTL4 (rhANGPTL4) vs. Vehicle was evaluated on Brain edema, hematoma volume, and neurological functional recovery. Recombinant human ANGPTL4 reduced brain edema and hematoma volume and improved neurological functional recovery over 4 weeks compared with vehicle in a mouse model of intracerebral hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: